齐拉西酮联合改良电休克治疗首发精神分裂症患者的疗效及对血清p-mTOR和IL-18水平的影响

Efficacy of ziprasidone combined with modified electroconvulsive therapy for first-episode schizophrenia and its effect on serum levels of p-mTOR and IL-18

摘要:

目的 探讨齐拉西酮联合改良性电休克治疗首发精神分裂症患者疗效及对血清磷酸化雷帕霉素靶蛋白（p-mTOR）和白细胞介素-18（IL-18）水平的影响。方法 选取2017年10月—2018年12月十堰市中西医结合医院精神科初次诊断为精神分裂症的患者100例。随机分为对照组（采用齐拉西酮治疗）和观察组（采用齐拉西酮联合改良电休克治疗），每组50例。观察两组疗效和并发症，比较治疗前后血清p-mTOR、IL-18水平。结果 两组治疗有效率比较，观察组高于对照组（96.00% VS 80.00%，P?<0.05）；两组治疗前后阳性与阴性症状量表（PANSS）阳性症状、阴性症状、一般精神病理症状、PANSS总分、临床疗效总评量表（CGI）评分比较，差异有统计学意义（P?<0.05）。两组治疗后血清p-mTOR、IL-18水平下降（P?<0.05），观察组治疗后血清p-mTOR、IL-18水平低于对照组[（2.18±12.56）VS（3.36±1.23）、（162.13±20.84）pg/ml VS （211.89±25.21）pg/ml，P?<0.05]，观察组不良反应率低于对照组（4.00% VS 20.00%，P?<0.05）。结论 齐拉西酮联合改良性电休克治疗首发精神分裂症疗效可靠，可降低血清p-mTOR、IL-18水平，不良反应少，效果优于单独接受齐拉西酮治疗。

Abstract:

Objective To investigate the effect of ziprasidone combined with modified electroconvulsive therapy on first-episode schizophrenia and its effect on serum phosphorylated rapamycin target protein (p-mTOR) and interleukin-18 (IL-18). Methods Totally 100 patients with first diagnosed schizophrenia were randomly divided into two groups. The control group (50 cases) received ziprasidone, while the observation group (50 cases) received ziprasidone combined with modified electroconvulsive therapy. The curative effect and complications of the two groups were observed. The changes of serum p-mTOR and IL-18 before and after treatment and the differences between the two groups were observed. Results There was significant difference in the effective rate between the two groups (96.00% VS 80.00%, P?